REFERENCES
- Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32–7
- Lidegaard O, Edstroem B, Kreiner S. Oral contraceptives and venous thromboembolism: a five- year national case–control study. Contraception 2002; 65:187–96
- Vessey MP. Female hormones and vascular disease – an epidemiological overview. Br J Fam Plann 1980;6:1–12
- Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997;78:327–33
- Guillebaud J. Contraception – Your Questions Answered, 3rd edn. Edinburgh: Churchill Livingstone, 1999
- Fotherby K. Clinical experience, and pharmacological effects of an oral contraceptive containing 20 mg oestrogen. Contraception 1992;46:477–88
- Lammers P, op ten Berg M. Phase III clinical trial with new oral contraceptive containing 150 mcg deso- gestrel and 20 mcg ethinylestradiol. Acta Obstet Gynecol Scand 1991;70:497–500
- Rossmanith WG, Wirth U, Gasser S, et al. Comparative study of ovarian activity, cycle stability and tolerance during administration of two low-dosage oral contra- ceptives. Zentralbl Gynakol 1997;119:538–44
- Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 mg ethinylestradiol and either 150 mg desogestrel or 75 mg gestodene. Eur J Contracept Reprod Health Care 1998:3:179–89
- Castelo-Branco C, Martinez de Osaba MJ, Pons F, et al. Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. Eur J Contracept Reprod Health Care 1998;3:79–84
- Egarter C, Topcuoglu MA, Imhof M, et al. Low dose oral contraceptives and quality of life. Contraception 1999;59:287–91
- Endicott J, Nee J, Harrision W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993:29:321–6
- Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996;41:423–9
- Mango D, Ricci S, Manna P, et al. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996;53:163–70
- Newton JR. Classification and comparison of oral contraceptives containing new generation progesto- gens. Hum Reprod Update 1995;1:231–63
- Benagiano G, Primiero FM. Multicenter clinical trial of an oral contraceptive with desogestrel plus 20 mcg ethinylestradiol in Italy. In Newton, JR, ed. Mercilon; a New Era in Low-dose Oral Contraception; the Proceedings of a Symposium Held at the 13th World Congress on Fertility and Sterility, Marrakesh, October 1989. Carnforth, UK: Parthenon Publishing, 1990:55–63
- Op ten Berg M. International multicenter clinical trial of an oral contraceptive containing 20 mcg ethinyl- estradiol and 150 mcg desogestrel (Mercilon). In Newton JR, op ten Berg M, eds. Optimizing the Estrogen Dose in Oral Contraceptives. Carnforth, UK: Parthenon Publishing, 1992:33–8
- Kahn-Nathan J, Lapousterle C. Results of a national multicentre study of an oral contraceptive containing 20 mcg ethinylestradiol and 150 mcg desogestrel. Reprod Hum Horm 1991;4 (Suppl 1): 15–20
- Deijen JB, Duyn KJ, Jansen WA, et al. Use of a low-dose oral contraceptive in relation to mental functioning. Contraception 1992;46:359–67
- Åkerlund M, Roede A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of 2 oral contraceptive formulations containing 150 mcg desogestrel and either 30 mcg or 20 mcg ethinyl- estradiol. Br J Obstet Gynaecol 1993;100:832–8
- Endrikat J, Jaques MA, Mayerhofer M, Pelissier C, Mueller U, Duesterberg B. A twelve-month compara- tive clinical investigation of two low-dose oral contra- ceptives containing 20 mcg ethinylestradiol/75 mcg gestodene and 20 mcg ethinylestradiol/150 mcg deso- gestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995:52:229–35
- Tuiten A, Panhuysen G, Koppeschaar E, et al. Stress, serotonergic function, and mood in users of oral contra- ceptives. Psychoneuroendocrinology 1995;20:323–34
- Endrikat J, Düsterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low- dose oral contraceptives in a multicenter clinical study. Contraception 1999;60:269–74